UK Markets open in 3 hrs 59 mins

Tonix Pharmaceuticals Holding Corp. (0A4T.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.6612-0.0605 (-8.38%)
At close: 5:59PM BST
Full screen
Previous close0.7217
Open0.6612
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.6612 - 0.6612
52-week range0.6612 - 0.6612
Volume5,000
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)1.35
PE ratio (TTM)N/A
EPS (TTM)-0.3960
Earnings date09 Aug 2021 - 13 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Why Tonix Pharmaceuticals Holding Is Rising Today
    Motley Fool

    Why Tonix Pharmaceuticals Holding Is Rising Today

    Troubled biotech Tonix Pharmaceuticals Holding (Nasdaq:TNXP) wasn't having a bad time of it on Monday. In mid-afternoon, the shares were trading marginally higher, likely because of the announcement of a new company facility. Tonix divulged in a press release that on Tuesday, it will conduct a groundbreaking ceremony at a new manufacturing facility in southeastern Massachusetts.

  • Is There Any Hope for Tonix Pharmaceuticals Stock?
    Motley Fool

    Is There Any Hope for Tonix Pharmaceuticals Stock?

    Tonix Pharmaceuticals (NASDAQ: TNXP) investors are having a bad week. Hot off the heels of a devastating interim analysis from one of its late-stage clinical trials that looks all but doomed to end in failure, the stock's price has fallen well below $1. Given that its other late-stage programs target notoriously difficult-to-treat conditions, including post-traumatic stress disorder (PTSD) and Alzheimer's disease, the entire company is looking quite frail.

  • Why Tonix Pharmaceuticals Stock Is Crashing Today
    Motley Fool

    Why Tonix Pharmaceuticals Stock Is Crashing Today

    Shares of Tonix Pharmaceuticals (NASDAQ: TNXP) were crashing 28.3% lower as of 10:24 a.m. EDT on Monday. The big decline came after Tonix announced on Friday following the market close that it is halting enrollment in a late-stage clinical study evaluating TNX-102 SL in treating fibromyalgia. Tonix made the decision to stop enrollment in its late-stage study of TNX-102 SL after the study's Independent Data Monitoring Committee (IDMC) completed an interim analysis.